Winer, Eric P.

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy

Morrow, P. K., Wulf, G. M., Ensor, J., Booser, D. J., Moore, J. A., Flores, P. R., Xiong, Y., Zhang, S., Krop, I. E., Winer, E. P., et al. (2011) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 209

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002

Winer, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesEstrogen and related hormone effects

Cited by 200

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E., Naughton, M., Goetz, M. P., Russell, C., et al. (2017) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 193

Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer

Lipsyc-Sharf, M., de Bruin, E. C., Santos, K., McEwen, R., Stetson, D., Patel, A., Kirkner, G. J., Hughes, M. E., Tolaney, S. M., Partridge, A. H., et al. (2022) · Journal of Clinical Oncology

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 152

Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.

Peppercorn, J., Blood, E., Winer, E., & Partridge, A. (2007) · Cancer

Pharmaceutical industry and healthcareGlobal Public Health Policies and Epidemiology

Cited by 123

Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

Petrelli, N. J., Winer, E. P., Brahmer, J., Dubey, S., Smith, S., Thomas, C., Vahdat, L. T., Obel, J., Vogelzang, N., Markman, M., et al. (2009) · Journal of Clinical Oncology

Science, Research, and MedicineHealth and Medical Research Impacts

Cited by 121

Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

Rugo, H. S., Loi, S., Adams, S., Schmid, P., Schneeweiss, A., Barrios, C. H., Iwata, H., Dieras, V. C., Winer, E. P., Kockx, M., et al. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 116

Impact of a pre-operative exercise intervention on breast cancer proliferation and gene expression: results from the Pre-Operative Health and Body (PreHAB) Study

Ligibel, J. A., Dillon, D., Giobbie-Hurder, A., McTiernan, A., Frank, E., Cornwell, M., Pun, M., Campbell, N., Dowling, R. J. O., Chang, M. C., et al. (2019) · Clinical Cancer Research

Cancer Risks and FactorsCancer survivorship and care

Cited by 100

Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901

Sheppard, V. B., Faul, L. A., Luta, G., Clapp, J. D., Yung, R. L., Wang, J. H.-Y., Kimmick, G., Isaacs, C., Tallarico, M., Barry, W. T., et al. (2014) · Journal of Clinical Oncology

Frailty in Older AdultsBreast Cancer Treatment Studies

Cited by 91

Pharmacokinetics and clinical impact of all- trans retinoic acid in metastatic breast cancer: a phase II trial

Sutton, L. M., Warmuth, M. A., Petros, W. P., & Winer, E. P. (1997) · Cancer Chemotherapy and Pharmacology

Retinoids in leukemia and cellular processesBreast Cancer Treatment Studies

Cited by 61